2019
Impact of early antiretroviral treatment on sexual behaviour: a randomised comparison
Lampe FC, Rodger AJ, Burman W, Grulich A, Friedland G, Sadr WE, Neaton J, Corbelli GM, Emery S, Molina JM, Orkin C, Gatell J, Gerstoft J, Ruxrungtham K, de Souza M, Phillips AN. Impact of early antiretroviral treatment on sexual behaviour: a randomised comparison. AIDS 2019, 33: 2337-2350. PMID: 31764099, PMCID: PMC6882545, DOI: 10.1097/qad.0000000000002359.Peer-Reviewed Original ResearchConceptsEarly antiretroviral treatmentHIV-serodifferent partnersAntiretroviral treatmentMonth 12Month 24CD4 cell countHIV-positive adultsSexual behaviorHIV infectiousnessImmediate armViral suppressionPrimary outcomeHigh prevalenceCondomless sexCell countMSMCells/Lower absolute levelsSexHeterosexual menTreatmentHeterosexualsArmAbsolute levelsPrevalence
2015
What motivates use of community-based human immunodeficiency virus testing in rural South Africa?
Upadhya D, Moll AP, Brooks RP, Friedland G, Shenoi SV. What motivates use of community-based human immunodeficiency virus testing in rural South Africa? International Journal Of STD & AIDS 2015, 27: 662-671. PMID: 26134323, PMCID: PMC4851612, DOI: 10.1177/0956462415592789.Peer-Reviewed Original ResearchConceptsHIV testingRural South AfricaRural resource-limited settingsHuman immunodeficiency virus (HIV) testingCommunity-based HIVCommunity-based testingMedian CD4 countRecent HIV exposureCommunity-based HIV testing programmeFirst-time testersHIV testing programsVoluntary HIV testingResource-limited settingsCD4 countHIV exposureMedian ageHIV statusVirus testingCommunity testingHIVCells/Rural settingsFamily membersSix-itemRisky lifestyles
2012
Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting
Gandhi N, Andrews J, Brust J, Montreuil R, Weissman D, Heo M, Moll A, Friedland G, Shah N. Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting. The International Journal Of Tuberculosis And Lung Disease 2012, 16: 90-97. PMID: 22236852, PMCID: PMC3302205, DOI: 10.5588/ijtld.11.0153.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsAnti-Retroviral AgentsAntitubercular AgentsCD4 Lymphocyte CountCoinfectionDrug Resistance, Multiple, BacterialExtensively Drug-Resistant TuberculosisFemaleHIV InfectionsHumansMaleMarkov ChainsMonte Carlo MethodPrevalencePrognosisProportional Hazards ModelsRetrospective StudiesRisk AssessmentRisk FactorsSouth AfricaSurvival AnalysisTime FactorsTuberculosis, Multidrug-ResistantTuberculosis, PulmonaryConceptsHuman immunodeficiency virusXDR-TB patientsRisk factorsAntiretroviral therapyXDR-TBDrug-resistant (XDR) TBImmunosuppressed human immunodeficiency virusStrong independent risk factorHigh HIV prevalence settingsMDR-TB patientsTB treatment programsIndependent risk factorYear of diagnosisDrug-resistant tuberculosisHIV prevalence settingsCells/Principal risk factorsCase-control studyAmplification of resistanceHigh mortality rateART initiationHIV testingImmunodeficiency virusPrevalence settingsMortality rate
2008
A randomized comparison of two instruments for measuring self-reported antiretroviral adherence
Mannheimer S, Thackeray L, Hullsiek K, Chesney M, Gardner E, Wu A, Telzak E, Lawrence J, Baxter J, Friedland G, Aids F. A randomized comparison of two instruments for measuring self-reported antiretroviral adherence. AIDS Care 2008, 20: 161-169. PMID: 18293124, DOI: 10.1080/09540120701534699.Peer-Reviewed Original ResearchConceptsSelf-reported adherenceImmunologic outcomesAntiretroviral adherenceStudy visitRecall instrumentSelf-reported antiretroviral adherenceCD4 cells/HIV resistance mutationsMultidrug-resistant HIVSelf-report instrumentVirologic failureAntiretroviral medicationsHIV diseaseMonth 12Randomized comparisonClinical trialsTreatment strategiesAdherence levelsResistance mutationsAdherenceCells/VisitsTrialsDaysMedian
2006
Sustained Benefit From a Long-Term Antiretroviral Adherence Intervention
Mannheimer SB, Morse E, Matts JP, Andrews L, Child C, Schmetter B, Friedland GH. Sustained Benefit From a Long-Term Antiretroviral Adherence Intervention. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2006, 43: s41-s47. PMID: 17091022, DOI: 10.1097/01.qai.0000245887.58886.ac.Peer-Reviewed Original ResearchConceptsAdherence supportAdherence interventionsClinical trialsMedian baseline CD4 countLong-term medication adherenceLarge randomized clinical trialsMM participantsAntiretroviral Adherence InterventionARV-naive individualsBaseline CD4 countFirst virologic failureIntervention clinical trialsRandomized clinical trialsMedication managersCD4 countVirologic failureVirologic outcomesCD4 cellsARV therapyHIV outcomesMedication adherenceMM subgroupsMM groupCluster randomizationCells/
2004
A Pilot Study of Once-Daily Antiretroviral Therapy Integrated With Tuberculosis Directly Observed Therapy in a Resource-Limited Setting
Jack C, Lalloo U, Karim QA, Karim SA, El-Sadr W, Cassol S, Friedland G. A Pilot Study of Once-Daily Antiretroviral Therapy Integrated With Tuberculosis Directly Observed Therapy in a Resource-Limited Setting. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2004, 36: 929-934. PMID: 15220699, DOI: 10.1097/00126334-200408010-00006.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdolescentAdultAlkynesAntibiotics, AntitubercularAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveBenzoxazinesCosts and Cost AnalysisCyclopropanesDidanosineDrug Therapy, CombinationFemaleHIV InfectionsHumansLamivudineMaleMiddle AgedOutpatient Clinics, HospitalOxazinesPilot ProjectsSouth AfricaTreatment OutcomeTuberculosisUrban PopulationConceptsAntiretroviral therapyTB therapyViral loadPilot studyTwenty HIV-positive patientsSmear-positive pulmonary TBCD4 count increaseDrug-sensitive TBObserved therapy programStandard TB therapyActive antiretroviral therapyHIV-positive patientsMean CD4 countMean viral loadCells/Resource limited settingsResource-limited settingsDaily didanosineHAART regimenCD4 countHIV clinicPulmonary TBTB clinicNeurologic toxicityObserved therapyDeveloping a Directly Administered Antiretroviral Therapy Intervention for HIV-Infected Drug Users: Implications for Program Replication
Altice FL, Mezger JA, Hodges J, Bruce RD, Marinovich A, Walton M, Springer SA, Friedland GH. Developing a Directly Administered Antiretroviral Therapy Intervention for HIV-Infected Drug Users: Implications for Program Replication. Clinical Infectious Diseases 2004, 38: s376-s387. PMID: 15156426, DOI: 10.1086/421400.Peer-Reviewed Original ResearchConceptsMedian HIV-1 RNA loadDrug usersHIV-1 RNA loadMost subjectsHuman immunodeficiency virusSelf-administered therapySyringe exchange programsMedian CD4Antiretroviral therapyDaily regimensMedical comorbiditiesImmunodeficiency virusEmergency departmentRNA loadMethadone clinicsMedication administrationOwn medicationsCopies/Major depressionMedical appointmentsTherapy interventionCell countDAARTCells/Medical services
2002
The Consistency of Adherence to Antiretroviral Therapy Predicts Biologic Outcomes for Human Immunodeficiency Virus—Infected Persons in Clinical Trials
Mannheimer S, Friedland G, Matts J, Child C, Chesney M, AIDS T. The Consistency of Adherence to Antiretroviral Therapy Predicts Biologic Outcomes for Human Immunodeficiency Virus—Infected Persons in Clinical Trials. Clinical Infectious Diseases 2002, 34: 1115-1121. PMID: 11915001, DOI: 10.1086/339074.Peer-Reviewed Original ResearchConceptsHIV RNA levelsHuman immunodeficiency virusImmunodeficiency virusClinical trialsRNA levelsPlasma HIV RNA levelsBiologic outcomesConsistency of adherenceCopies/mLMulticenter clinical trialAntiretroviral therapyCD4 countMonth 12Nonwhite racePoor adherenceAdherence levelsAdherence patternsOlder ageGood adherenceAdherenceCells/TrialsVisitsOutcomesParticipants
2000
In Vivo Antagonism with Zidovudine plus Stavudine Combination Therapy
Havlir D, Tierney C, Friedland G, Pollard R, Smeaton L, Sommadossi J, Fox L, Kessler H, Fife K, Richman D. In Vivo Antagonism with Zidovudine plus Stavudine Combination Therapy. The Journal Of Infectious Diseases 2000, 182: 321-325. PMID: 10882616, DOI: 10.1086/315683.Peer-Reviewed Original ResearchConceptsCD4 cell countD4TCell countD4T armD4T monotherapyWeeks of therapyHuman immunodeficiency virusCopies/mLGreater antiviral activityT monotherapyHIV RNACurrent regimenImmunodeficiency virusPharmacologic antagonismCombination therapyMean reductionZidovudineAntiviral activityVivo antagonismProgressive declinePatientsCells/DdIIntracellular levelsTherapy